SARS-CoV-2 getting into the brain;neurological phenotype of COVID-19,and management by nano-biotechnology

Human coronavirus infection getting into the brain:By February 2022,the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection,causing the coronavirus disease 2019(COVID-19)outbreak,has infected around 415 million people,and caused~5.8 million deaths worldwide(WHO,https://covid19.who.int/).As SARS-CoV-2 replicates during the infection,it undergoes genetic mutation to generate variants with varying characteristics and mutation frequencies.The emerging,over time,new variants that differ with transmissibility,immunity,and infection severity pose continuous challenges to established COVID-19 management strategies and regulations.Several SARS-CoV-2 variants such as Omicron(B.1.1.529),Delta(B.1.617.2),UK(B.1.17),South Africa(B.1.351),Brazil(P.1),and New York B.1.525-B.1.526 were detected worldwide and accelerated severity of COVID-19 pandemic(Figure 1A;McQuaid et al.,2021).